What Merck & Moderna's Cancer Vaccine Breakthrough Means for CancerVax — A Conversation with CEO Byron Elton

​In August 2026, Moderna and Merck announced that their mRNA-based cancer vaccine met its primary endpoint in a Phase 3 trial — the first positive late-stage result for an mRNA cancer therapy in history.

​It's a watershed moment for the field. And it's directly relevant to CancerVax.

​Both companies use the same foundational technology — LNP-mRNA delivery — that CancerVax is building on. But CancerVax is pursuing a fundamentally different and potentially more scalable approach: instead of a personalized vaccine manufactured for each patient, CancerVax is developing an off-the-shelf universal cancer treatment that leverages immunity most people already have.

​Join us for a live conversation with CancerVax CEO Byron Elton as he breaks down what the Merck/Moderna news means for the cancer vaccine field, why CancerVax's approach is designed to go further, and where the company stands today.

​Topics we'll cover:

• ​What the INTerpath-001 Phase 3 results actually validated

• ​How CancerVax's platform is similar — and where it diverges

• ​Why an off-the-shelf approach could have major advantages in cost and scale

• ​CancerVax's current scientific progress and what's next

• ​How investors can participate in CancerVax's live raise on StartEngine

​This Reg CF offering is made available through StartEngine Primary, LLC, member FINRA/SIPC. This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment.